Hence then, the article about astellas announces zolbetuximab meets primary endpoint in phase 3 glow trial as first line treatment in claudin 18 2 positive her2 negative locally advanced unresectable or metastatic gastric and gastroesophageal junction gej cancers was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 GLOW Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-negative Locally Advanced Unresectable or Metastatic Gastric and Gastroesophageal Junction (GEJ) Cancers )
Also on site :
- US Congressman denies existence of Palestinians in interview
- Secret British Army documents found in garbage dump – Sun
- Adam Sandler Shared One Piece of Marriage Advice to Taylor Swift and Travis Kelce Guests Won't Forget